Yusuke Nakamura to Protein Kinase Inhibitors
This is a "connection" page, showing publications Yusuke Nakamura has written about Protein Kinase Inhibitors.
Connection Strength
2.657
-
Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor. Oncotarget. 2016 Apr 05; 7(14):18171-82.
Score: 0.408
-
T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia. Oncotarget. 2015 Oct 20; 6(32):33410-25.
Score: 0.395
-
A unique hinge binder of extremely selective aminopyridine-based Mps1 (TTK) kinase inhibitors with cellular activity. Bioorg Med Chem. 2015 May 01; 23(9):2247-60.
Score: 0.379
-
TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis. Sci Transl Med. 2014 Oct 22; 6(259):259ra145.
Score: 0.369
-
MELK inhibitor, novel molecular targeted therapeutics for human cancer stem cells. Cell Cycle. 2013 Jun 01; 12(11):1655-6.
Score: 0.334
-
Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models. Cancer Med. 2020 01; 9(1):324-334.
Score: 0.131
-
WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer. Sci Rep. 2017 01 19; 7:40664.
Score: 0.108
-
Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells. Blood Cancer J. 2016 08 19; 6(8):e460.
Score: 0.105
-
Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells. Oncotarget. 2016 Apr 05; 7(14):17652-64.
Score: 0.102
-
Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations. J Clin Oncol. 2016 06 20; 34(18):2165-71.
Score: 0.102
-
Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity. J Med Chem. 2015 Feb 26; 58(4):1760-75.
Score: 0.094
-
Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Oncotarget. 2012 Dec; 3(12):1629-40.
Score: 0.081
-
T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer. Clin Cancer Res. 2016 Dec 15; 22(24):6110-6117.
Score: 0.026
-
VAV3 mediates resistance to breast cancer endocrine therapy. Breast Cancer Res. 2014 May 28; 16(3):R53.
Score: 0.022